The Emerging Specialty of Cardio-Rheumatology

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2024 Jun 24

PMID 38913292

Authors

Malek Nayfeh

Helene DiGregorio

Jean Michel Saad

Mouaz Al-Mallah

Mahmoud Al Rifai

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: In this review, we aimed to summarize the different aspects of the field of cardio-rheumatology, the role of the cardio-rheumatologist, and future research in the field.

Recent Findings: Cardio-rheumatology is an emerging subspecialty within cardiology that focuses on addressing the intricate relationship between systemic inflammation and cardiovascular diseases. It involves understanding the cardiovascular impact of immune-mediated inflammatory diseases on the heart and vascular system. A cardio-rheumatologist's role is multifaceted. First, they should understand the cardiac manifestations of rheumatological diseases. They should also be knowledgeable about the different immunotherapies available and side effects. Additionally, they should know how to utilize imaging modalities, either for diagnosis, prognosis, or treatment monitoring. This field is constantly evolving with new research on both treatment and imaging of the effects of inflammation on the cardiovascular system.

References

Boyalla V, Gallego-Colon E, Spartalis M . Immunity and inflammation in cardiovascular disorders. BMC Cardiovasc Disord. 2023; 23(1):148. PMC: 10035189. DOI: 10.1186/s12872-023-03185-z. View

Jagpal A, Navarro-Millan I . Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol. 2019; 2:10. PMC: 6390616. DOI: 10.1186/s41927-018-0014-y. View

Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic M, Ronda N . Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005; 112(21):3337-47. DOI: 10.1161/CIRCULATIONAHA.104.507996. View

Popa-Fotea N, Ferdoschi C, Micheu M . Molecular and cellular mechanisms of inflammation in atherosclerosis. Front Cardiovasc Med. 2023; 10:1200341. PMC: 10434786. DOI: 10.3389/fcvm.2023.1200341. View

Zhang K, Huang X, Li X, Feng M, Li L, Cai X . Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase α1 via a mitogen-activated protein kinase and c-Jun pathway. Arch Biochem Biophys. 2012; 528(2):127-33. DOI: 10.1016/j.abb.2012.09.007. View

Gulick T, Chung M, PIEPER S, Lange L, Schreiner G . Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989; 86(17):6753-7. PMC: 297924. DOI: 10.1073/pnas.86.17.6753. View

Yokoyama T, Vaca L, Rossen R, Durante W, Hazarika P, Mann D . Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993; 92(5):2303-12. PMC: 288411. DOI: 10.1172/JCI116834. View

Yu X, Kennedy R, Liu S . JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem. 2003; 278(18):16304-9. DOI: 10.1074/jbc.M212321200. View

Toldo S, Mezzaroma E, OBrien L, Marchetti C, Seropian I, Voelkel N . Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2014; 306(7):H1025-31. PMC: 3962640. DOI: 10.1152/ajpheart.00795.2013. View

10.

Bansal S, Ismahil M, Goel M, Patel B, Hamid T, Rokosh G . Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure. Circ Heart Fail. 2017; 10(3):e003688. PMC: 5331621. DOI: 10.1161/CIRCHEARTFAILURE.116.003688. View

11.

Scarpioni R, Ricardi M, Albertazzi V . Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. World J Nephrol. 2016; 5(1):66-75. PMC: 4707170. DOI: 10.5527/wjn.v5.i1.66. View

12.

Chiabrando J, Bonaventura A, Vecchie A, Wohlford G, Mauro A, Jordan J . Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(1):76-92. DOI: 10.1016/j.jacc.2019.11.021. View

13.

Asopa S, Patel A, Khan O, Sharma R, Ohri S . Non-bacterial thrombotic endocarditis. Eur J Cardiothorac Surg. 2007; 32(5):696-701. DOI: 10.1016/j.ejcts.2007.07.029. View

14.

Guillevin L, Dorner T . Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Ther. 2007; 9 Suppl 2:S9. PMC: 2072881. DOI: 10.1186/ar2193. View

15.

Avina-Zubieta J, Choi H, Sadatsafavi M, Etminan M, Esdaile J, Lacaille D . Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59(12):1690-7. DOI: 10.1002/art.24092. View

16.

Villa-Forte A, Mandell B . [Cardiovascular disorders and rheumatic disease]. Rev Esp Cardiol. 2011; 64(9):809-17. DOI: 10.1016/j.recesp.2011.05.009. View

17.

Roman M, Salmon J . Cardiovascular manifestations of rheumatologic diseases. Circulation. 2007; 116(20):2346-55. DOI: 10.1161/CIRCULATIONAHA.106.678334. View

18.

Cathcart E, Spodick D . Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis. N Engl J Med. 1962; 266:959-64. DOI: 10.1056/NEJM196205102661901. View

19.

Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Ollier W . Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2004; 33(4):231-8. DOI: 10.1053/j.semarthrit.2003.09.011. View

20.

Guedes C, Cormier B, Barthelemy B, Rat A, Boissier M . Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum. 2001; 45(2):129-35. DOI: 10.1002/1529-0131(200104)45:2<129::AID-ANR164>3.0.CO;2-K. View